Enlivex Therapeutics (ENLV) Competitors $1.01 -0.02 (-1.46%) Closing price 03:59 PM EasternExtended Trading$1.02 +0.01 (+0.49%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. ANRO, ANEB, CNTB, CRVO, IPA, ANIX, ALTS, VIRI, ENTX, and ORMPShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Alto Neuroscience (ANRO), Anebulo Pharmaceuticals (ANEB), Connect Biopharma (CNTB), CervoMed (CRVO), ImmunoPrecise Antibodies (IPA), Anixa Biosciences (ANIX), ALT5 Sigma (ALTS), Virios Therapeutics (VIRI), Entera Bio (ENTX), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Its Competitors Alto Neuroscience Anebulo Pharmaceuticals Connect Biopharma CervoMed ImmunoPrecise Antibodies Anixa Biosciences ALT5 Sigma Virios Therapeutics Entera Bio Oramed Pharmaceuticals Enlivex Therapeutics (NASDAQ:ENLV) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment. Which has more risk and volatility, ENLV or ANRO? Enlivex Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Which has higher earnings and valuation, ENLV or ANRO? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.58-1.75Alto NeuroscienceN/AN/A-$61.43M-$2.39-1.48 Do institutionals & insiders have more ownership in ENLV or ANRO? 1.0% of Enlivex Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 11.1% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ENLV or ANRO more profitable? Alto Neuroscience's return on equity of -44.34% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -58.31% -50.32% Alto Neuroscience N/A -44.34%-36.73% Does the media refer more to ENLV or ANRO? In the previous week, Alto Neuroscience had 20 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 31 mentions for Alto Neuroscience and 11 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.89 beat Alto Neuroscience's score of 0.26 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 4 Very Positive mention(s) 1 Positive mention(s) 25 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ENLV or ANRO? Enlivex Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 885.22%. Alto Neuroscience has a consensus target price of $8.50, indicating a potential upside of 140.79%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryEnlivex Therapeutics beats Alto Neuroscience on 7 of the 13 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.36M$2.61B$5.83B$10.07BDividend YieldN/A48.62%5.25%4.53%P/E Ratio-1.7523.7375.5726.01Price / SalesN/A656.95536.77117.75Price / CashN/A169.9337.4259.95Price / Book1.025.2711.536.20Net Income-$15.01M$32.95M$3.29B$270.65M7 Day Performance-4.25%1.34%0.44%2.77%1 Month Performance-29.02%30.71%10.84%8.83%1 Year Performance-19.95%2.03%61.62%27.49% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.3036 of 5 stars$1.02-1.5%$10.00+885.2%-14.2%$24.36MN/A-1.7570News CoverageANROAlto Neuroscience2.8708 of 5 stars$3.91+6.5%$8.50+117.4%-73.2%$99.37MN/A-1.64N/ATrending NewsANEBAnebulo Pharmaceuticals1.8175 of 5 stars$2.20-7.6%$5.50+150.0%+15.2%$97.78MN/A-8.464High Trading VolumeCNTBConnect Biopharma3.0384 of 5 stars$1.79+2.3%$7.00+291.1%+39.7%$97.51M$26.03M0.00110Gap DownCRVOCervoMed3.4688 of 5 stars$9.99-4.9%$19.29+93.1%-37.4%$97.25M$9.74M-3.834News CoveragePositive NewsAnalyst ForecastIPAImmunoPrecise Antibodies2.5706 of 5 stars$2.10+8.5%$4.00+90.9%+220.8%$96.68M$17.59M-3.0880Upcoming EarningsGap DownANIXAnixa Biosciences2.7918 of 5 stars$2.98+0.3%$9.00+202.0%-6.0%$95.67M$210K-7.845News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastALTSALT5 Sigma0.3598 of 5 stars$4.13-5.9%N/A+90.0%$94.97M$12.53M0.00170VIRIVirios TherapeuticsN/A$4.90-2.0%$5.00+2.0%+2,607.2%$94.36MN/A-18.155Gap DownENTXEntera Bio1.6674 of 5 stars$2.00-2.9%$10.00+400.0%-0.5%$94.07M$180K-7.6920Short Interest ↓Gap UpHigh Trading VolumeORMPOramed Pharmaceuticals0.4807 of 5 stars$2.30+3.1%N/A-4.1%$91.44M$1.34M-6.5710Positive News Related Companies and Tools Related Companies ANRO Competitors ANEB Competitors CNTB Competitors CRVO Competitors IPA Competitors ANIX Competitors ALTS Competitors VIRI Competitors ENTX Competitors ORMP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts